FDA declined to approve Amphastar Pharmaceuticals Inc.'s new drug application for a nasal spray formulation of naloxone until the company addresses several issues with the opioid overdose reversal agent.
Amphastar announced on Feb. 21 that it had received a complete response letter (CRL) for its NDA from FDA that...






